Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
pharmaphorum
OCTOBER 26, 2022
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis and other interstitial lung diseases (ILDs). First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5
Let's personalize your content